Pacific Biosciences of California, Inc.

NasdaqGS:PACB Stock Report

Market Cap: US$471.0m

Pacific Biosciences of California Valuation

Is PACB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PACB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PACB ($1.72) is trading below our estimate of fair value ($3.66)

Significantly Below Fair Value: PACB is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PACB?

Key metric: As PACB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PACB. This is calculated by dividing PACB's market cap by their current revenue.
What is PACB's PS Ratio?
PS Ratio2.7x
SalesUS$173.15m
Market CapUS$471.05m

Price to Sales Ratio vs Peers

How does PACB's PS Ratio compare to its peers?

The above table shows the PS ratio for PACB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.2x
CDXC ChromaDex
6.3x18.1%US$575.7m
MLAB Mesa Laboratories
2.3x5.5%US$541.8m
SLGC Standard BioTools
4.8x16.4%US$396.2m
QTRX Quanterix
3.3x14.4%US$424.5m
PACB Pacific Biosciences of California
2.7x19.6%US$471.0m

Price-To-Sales vs Peers: PACB is good value based on its Price-To-Sales Ratio (2.7x) compared to the peer average (4.2x).

Price to Sales Ratio vs Industry

How does PACB's PS Ratio compare vs other companies in the US Life Sciences Industry?

10 CompaniesPrice / SalesEstimated GrowthMarket Cap
FTRE Fortrea Holdings
0.6x2.4%US$1.68b
ATLN Atlantic International
0.6xn/aUS$253.24m
NOTV Inotiv
0.2x7.5%US$72.55m
SNCE Science 37 Holdings
0.6x17.5%US$34.67m
PACB 2.7xIndustry Avg. 3.2xNo. of Companies11PS02.85.68.411.214+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: PACB is good value based on its Price-To-Sales Ratio (2.7x) compared to the US Life Sciences industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is PACB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PACB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.7x
Fair PS Ratio4.3x

Price-To-Sales vs Fair Ratio: PACB is good value based on its Price-To-Sales Ratio (2.7x) compared to the estimated Fair Price-To-Sales Ratio (4.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PACB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.72
US$3.07
+78.4%
37.8%US$6.00US$2.00n/a11
Nov ’25US$2.44
US$3.09
+26.7%
44.6%US$7.00US$2.00n/a11
Oct ’25US$1.62
US$3.00
+85.2%
47.1%US$7.00US$2.00n/a11
Sep ’25US$1.37
US$3.00
+119.0%
47.1%US$7.00US$2.00n/a11
Aug ’25US$1.92
US$4.25
+121.4%
71.8%US$13.00US$2.00n/a12
Jul ’25US$1.20
US$4.25
+254.2%
71.8%US$13.00US$2.00n/a12
Jun ’25US$1.79
US$4.27
+138.7%
74.6%US$13.00US$2.00n/a11
May ’25US$1.69
US$5.82
+244.3%
60.5%US$13.00US$2.50n/a11
Apr ’25US$3.65
US$10.05
+175.2%
22.9%US$15.00US$6.50n/a11
Mar ’25US$5.19
US$10.54
+103.1%
23.7%US$15.00US$6.50n/a12
Feb ’25US$6.76
US$12.21
+80.6%
26.9%US$19.00US$8.00n/a12
Jan ’25US$9.81
US$11.92
+21.5%
27.9%US$19.00US$8.00n/a12
Dec ’24US$8.88
US$12.67
+42.6%
31.5%US$20.00US$8.00n/a12
Nov ’24US$5.97
US$13.00
+117.8%
29.3%US$20.00US$8.00US$2.4412
Oct ’24US$8.35
US$14.75
+76.6%
20.9%US$20.00US$9.00US$1.6212
Sep ’24US$11.41
US$15.55
+36.2%
15.1%US$20.00US$13.00US$1.3711
Aug ’24US$13.34
US$14.73
+10.4%
16.9%US$20.00US$12.00US$1.9211
Jul ’24US$13.30
US$14.73
+10.7%
16.9%US$20.00US$12.00US$1.2011
Jun ’24US$12.86
US$13.56
+5.4%
10.5%US$17.00US$12.00US$1.799
May ’24US$11.31
US$12.38
+9.4%
13.4%US$15.00US$10.00US$1.698
Apr ’24US$11.58
US$12.38
+6.9%
13.4%US$15.00US$10.00US$3.658
Mar ’24US$8.77
US$12.13
+38.3%
11.2%US$14.00US$10.00US$5.198
Feb ’24US$11.48
US$12.14
+5.8%
10.3%US$14.00US$10.00US$6.767
Jan ’24US$8.18
US$12.33
+50.8%
12.1%US$14.00US$10.00US$9.816
Dec ’23US$11.08
US$12.33
+11.3%
12.1%US$14.00US$10.00US$8.886
Nov ’23US$8.81
US$9.67
+9.7%
22.1%US$12.00US$6.00US$5.976

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$194.38

7D

-8.1%

1Y

-7.2%

Collegium Pharmaceutical

US$959.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.00

7D

-0.6%

1Y

15.5%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.10

7D

-7.9%

1Y

6.6%